Bartosz Hudzik: Better Control, Similar Tolerability With Quadruple Therapy in Resistant Hypertension
Bartosz Hudzik, Editorial Consultant at JACC Case Reports, shared a post on LinkedIn about a recent article by Stefano Taddei et al, published in European Society of Cardiology:
”Resistant hypertension is often treated as a dosing problem.
But what if it’s actually a strategy problem?
Patients with true resistant hypertension face markedly higher risks of stroke, heart failure, kidney disease, and death — yet many remain on prolonged triple therapy despite uncontrolled BP.
The Phase 3 QUADRO trial challenges that inertia.
Switching patients from standard triple therapy to the first full-dose quadruple single-pill combination (adding bisoprolol) delivered:
- −8 mmHg additional systolic BP reduction in just 8 weeks
- Confirmed improvement on 24-hour ambulatory monitoring
- No serious safety concerns
- A single pill instead of therapeutic escalation by fragmentation
In other words: better control, similar tolerability, potentially better adherence.
If resistant hypertension drives disproportionate cardiovascular risk, should we be escalating faster — and simplifying sooner?”
Title: Quadruple vs triple therapy for resistant hypertension: the QUADRO trial
Authors: Stefano Taddei, Krzysztof Narkiewicz, Stéphanie Bricout-Hennel, Parvoleta Petrova, Cécile Batailler, Roland Asmar
Read the Full Article on European Society of Cardiology․
Stay updated on all scientific advances with Hemostasis Today.
-
May 27, 2026, 09:58Omid Seidizadeh: Take The EAHAD Survey on Access to Diagnosis and Treatment for VWD Europe
-
May 27, 2026, 09:51Richard Benjamin: RedeS Phase III Trial Reaches Major Milestone in Advancing Pathogen-Reduced RBCs for Transfusion
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications